Ciencias de la Salud
Campo de conocimiento
![Foto de Ciencias de la Salud](/img/noimage.png)
![Foto de University of Texas Southwestern Medical Center](/img/noimage_org.png)
University of Texas Southwestern Medical Center
Dallas, Estados UnidosPublicaciones en colaboración con investigadoras/es de University of Texas Southwestern Medical Center (28)
2024
-
Correction to: SNCA genetic lowering reveals differential cognitive function of alpha-synuclein dependent on sex (Acta Neuropathologica Communications, (2022), 10, 1, (180), 10.1186/s40478-022-01480-y)
Acta Neuropathologica Communications
-
The “Woundosome” Concept and Its Impact on Procedural Outcomes in Patients With Chronic Limb-Threatening Ischemia
Journal of Endovascular Therapy
2023
-
Anti–Neutrophil Extracellular Trap Antibodies in Antiphospholipid Antibody–Positive Patients: Results From the Antiphospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking Clinical Database and Repository
Arthritis and Rheumatology, Vol. 75, Núm. 8, pp. 1407-1414
-
Global comment on the use of hydroxychloroquine during the periconception period and pregnancy in women with autoimmune diseases
The Lancet Rheumatology
2022
-
SNCA genetic lowering reveals differential cognitive function of alpha-synuclein dependent on sex
Acta Neuropathologica Communications, Vol. 10, Núm. 1
2021
-
Biomarkers for Traumatic Brain Injury: Data Standards and Statistical Considerations
Journal of Neurotrauma, Vol. 38, Núm. 18, pp. 2514-2529
-
Global wealth disparities drive adherence to COVID-safe pathways in head and neck cancer surgery
BJS Open
-
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1
Autophagy, Vol. 17, Núm. 1, pp. 1-382
-
Impact of Bacillus Calmette-Gue´rin (BCG) vaccination on postoperative mortality in patients with perioperative SARS-CoV-2 infection
BJS Open
2020
-
Corrigendum to ‘Global Vascular Guidelines on the Management of Chronic Limb-Threatening Ischemia’ (European Journal of Vascular & Endovascular Surgery (2019) 58(1S) (S1–S109.e33), (S1078588419303806), (10.1016/j.ejvs.2019.05.006))
European Journal of Vascular and Endovascular Surgery
-
Corrigendum to “Global Vascular Guidelines on the Management of Chronic Limb-Threatening Ischaemia” [Eur J Vasc Endovasc Surg 58 (1S) (2019) 1–109>] (European Journal of Vascular & Endovascular Surgery (2019) 58(1S) (S1–S109.e33), (S1078588419303806), (10.1016/j.ejvs.2019.05.006))
European Journal of Vascular and Endovascular Surgery
2019
-
Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial
The Lancet Respiratory Medicine, Vol. 7, Núm. 11, pp. 951-963
-
Global Vascular Guidelines on the Management of Chronic Limb-Threatening Ischemia
European Journal of Vascular and Endovascular Surgery, Vol. 58, Núm. 1, pp. S1-S109.e33
-
Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1
Antiviral Research, Vol. 170
2018
-
Efficacy and safety of lampalizumab for geographic atrophy due to age-related macular degeneration: Chroma and spectri phase 3 randomized clinical trials
JAMA Ophthalmology, Vol. 136, Núm. 6, pp. 666-677
-
Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study
The Lancet Neurology, Vol. 17, Núm. 6, pp. 548-558
2017
-
Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: A randomised, double-blind, phase III equivalence study
Annals of the Rheumatic Diseases, Vol. 76, Núm. 10, pp. 1679-1687
2016
2014
-
Interleukin-1 antagonism in type 1 diabetes of recent onset: Two multicenter, randomized double-masked, placebo-controlled trials
Diabetes Technology and Therapeutics